Country-specific cost-effectiveness of early intervention with budesonide in mild asthma

Martin J. Buxton, S. D. Sullivan, L. F. Andersson, C. J. Lamm, B. Liljas, W. W. Busse, S. Pedersen, K. B. Weiss

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention.

Original languageEnglish (US)
Pages (from-to)568-574
Number of pages7
JournalEuropean Respiratory Journal
Volume24
Issue number4
DOIs
StatePublished - Oct 1 2004

Keywords

  • Budesonide
  • Cost-effectiveness
  • Early intervention
  • Inhaled Steroid Treatment As Regualr Therapy in early asthma
  • International

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Country-specific cost-effectiveness of early intervention with budesonide in mild asthma'. Together they form a unique fingerprint.

  • Cite this

    Buxton, M. J., Sullivan, S. D., Andersson, L. F., Lamm, C. J., Liljas, B., Busse, W. W., Pedersen, S., & Weiss, K. B. (2004). Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. European Respiratory Journal, 24(4), 568-574. https://doi.org/10.1183/09031936.04.00108703